Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Tenaya Therapeutics (NASDAQ:TNYA) will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, Massachusetts, from August 11-12, 2026.

Rhea-AI Summary

Tenaya Therapeutics (NASDAQ:TNYA) will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, Massachusetts, from August 11-12, 2026. Members of management will host 1x1 investor meetings, and CFO Eric Hyllengren will take part in a fireside chat on Tuesday, August 11, 2026, at 12:30 p.m. ET.

A live webcast and 30-day replay will be available in the Investors section of Tenaya’s website. Tenaya highlights a clinical pipeline including gene therapies TN-201, TN-401 and small molecule TN-301 targeting heart and related conditions.

Argus Aug 5 session 16 alerts

+5.81% close to close 1.7x rel. volume Open Argus

Details

Market move: TNYA +5.81% in the Aug 5 session. conference participation

+5.6% Peak Tracked

-3.1% Trough Tracked

$174.57M Mkt Cap at Peak Alert

On Aug 5, the first trading day after this news, TNYA closed 5.81% above the previous close. Argus tracked a peak move of +5.6% during that session. Argus tracked a trough of -3.1% from its starting point during tracking. Our momentum scanner recorded 16 alerts for this stock that day. That session’s volume was 1.7x the stock’s average daily volume.

Data tracked by StockTitan Argus for the Aug 5 session.

Key Figures

Conference edition: 46th Annual Conference dates: August 11-12, 2026 Fireside chat: 12:30 pm ET +2 more

Conference edition

46th Annual

Canaccord Genuity Growth Conference

Conference dates

August 11-12, 2026

Boston, Massachusetts

Fireside chat

12:30 pm ET

Tuesday, August 11, 2026

Investor meetings

1x1

Management meetings at the conference

Replay availability

approximately 30 days

Following the conference

Historical Context

5 past events · Latest: Jul 14

5 events

1. Jul 14

   Inducement grants

   24h Move

   -2.5%

   Stock options granted to newly appointed CFO and two non-executive employees

2. Jun 29

   CFO appointment

   24h Move

   +2.4%

   Eric Hyllengren appointed CFO effective July 13, 2026

3. Jun 03

   Interim clinical data

   24h Move

   -0.5%

   TN-201 data showed cardiac remodeling and symptom reductions in evaluable patients

4. Jun 02

   Data announcement

   24h Move

   -0.5%

   Company scheduled interim MyPEAK-1 data release for June 3, 2026

5. May 29

   Conference participation

   24h Move

   +8.8%

   CEO scheduled to present at Jefferies Global Healthcare Conference

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

arvc, hdac6 inhibitor, hfpef, dmd

4 terms

arvc medical

"PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC)"

Acronym for arrhythmogenic right ventricular cardiomyopathy, a genetic heart muscle disease that causes scar tissue in the right ventricle and can lead to irregular heartbeats or heart failure. It matters to investors because research, diagnostics, treatments, and devices targeting this condition can drive clinical trial activity, regulatory filings, and potential market opportunities or liabilities in healthcare-related companies; think of it as a specific medical need that shapes product development and revenue potential.

hdac6 inhibitor medical

"a highly specific small molecule HDAC6 inhibitor"

An HDAC6 inhibitor is a drug that blocks the activity of the HDAC6 enzyme, which helps control how cells manage certain proteins and switch genes on or off. Think of HDAC6 as a combination of a light switch and a cleaning crew inside cells; inhibiting it can change cell behavior and reduce harmful protein buildup. Investors care because this mechanism underlies potential treatments for cancers, neurodegenerative and inflammatory diseases, so it shapes clinical risk, development timelines and market opportunity.

hfpef medical

"heart failure with preserved ejection fraction (HFpEF)"

Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure where the heart pumps out a normal percentage of blood but has trouble relaxing and filling, so overall blood flow to the body is reduced. For investors, HFpEF matters because it represents a large, growing patient population with substantial hospital costs and unmet treatment needs, making it a focus for drug development, clinical trials, and medical device opportunities.

dmd medical

"Duchenne muscular dystrophy (DMD)"

Duchenne muscular dystrophy (DMD) is a genetic disorder that causes progressive weakening of muscles, typically beginning in childhood, due to the absence of a critical muscle protein. For investors, DMD is important because it represents a well-defined patient population and a high unmet medical need, meaning successful therapies can command significant market value and influence regulatory decisions, trial design and long-term revenue potential—much like a niche product that fills a clear gap in demand.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that members of management will host 1x1 meetings with investors at the upcoming Canaccord Genuity 46^th Annual Growth Conference taking place from August 11-12, 2026 in Boston, Massachusetts. Eric Hyllengren, Tenaya’s Chief Financial Officer, will participate in a fireside chat on Tuesday, August 11, 2026, at 12:30 pm ET.

The live webcast of the fireside chat may be accessed from the Investors section of Tenaya’s website. An archived replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.

About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM); TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC); and TN-301, a highly specific small molecule HDAC6 inhibitor with broad potential clinical utility in cardiac, metabolic and muscular conditions, including heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD). Tenaya has employed a suite of integrated internal capabilities including modality agnostic target discovery and validation, to generate a portfolio of novel medicines based on genetic insights, aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.

Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com

Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Tenaya Therapeutics (NASDAQ:TNYA) present at the Canaccord Genuity 46th Annual Growth Conference in 2026?

Tenaya Therapeutics will participate in the Canaccord Genuity 46th Annual Growth Conference from August 11-12, 2026. According to Tenaya Therapeutics, CFO Eric Hyllengren’s fireside chat is scheduled for Tuesday, August 11, 2026, at 12:30 p.m. ET in Boston.

How can investors access the Tenaya Therapeutics (TNYA) fireside chat webcast from the August 11, 2026 conference?

Investors can access the live Tenaya Therapeutics fireside chat webcast via the Investors section of the company’s website. According to Tenaya Therapeutics, an archived replay will remain available on the website for approximately 30 days following the conference.

What is the focus of Tenaya Therapeutics’ pipeline mentioned ahead of the 2026 Canaccord conference?

Tenaya’s pipeline includes TN-201 for MYBPC3-associated HCM, TN-401 for PKP2-associated ARVC, and TN-301, an HDAC6 inhibitor. According to Tenaya Therapeutics, these programs target genetic heart diseases and related cardiac, metabolic, and muscular conditions.

Who from Tenaya Therapeutics will speak at the Canaccord Genuity 46th Annual Growth Conference in August 2026?

Eric Hyllengren, Chief Financial Officer of Tenaya Therapeutics, will participate in a fireside chat on August 11, 2026. According to Tenaya Therapeutics, management will also host 1x1 meetings with investors during the two-day Boston conference.

Where is the Canaccord Genuity 46th Annual Growth Conference featuring Tenaya Therapeutics (TNYA) being held?

The Canaccord Genuity 46th Annual Growth Conference featuring Tenaya Therapeutics is being held in Boston, Massachusetts from August 11-12, 2026. According to Tenaya Therapeutics, both in-person investor meetings and a webcasted fireside chat are planned during the event.

How long will the replay of Tenaya Therapeutics’ August 11, 2026 fireside chat be available to investors?

The replay of Tenaya Therapeutics’ August 11, 2026 fireside chat will be available for about 30 days. According to Tenaya Therapeutics, investors can access this archived webcast through the Investors section of the company’s website following the conference.